var data={"title":"Aminolevulinic acid (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Aminolevulinic acid (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/811786?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=aminolevulinic-acid-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Aminolevulinic acid (systemic): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50213753\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Diagnostic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50352172\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Glioma (optical imaging agent):</b> Oral: 20 mg/kg administered 3 hours (range: 2 to 4 hours) prior to the start of anesthesia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50352173\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50352174\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. Clearance may be reduced in patients with renal impairment; approximately one-third of a dose is excreted unchanged in the urine, however, it is not known if dosage adjustment is necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50352175\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. Clearance may be reduced in patients with hepatic impairment, however, it is not known if dosage adjustment is necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193062\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Gleolan: FDA approved June 2017; anticipated availability is currently undetermined</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50352177\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For oral administration only. Must be reconstituted by a health care provider prior to administration (see Preparation for Administration). Administer 3 hours (range 2 to 4 hours) prior to the start of anesthesia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193060\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Glioma (optical imaging agent):</b> Adjunct for visualization of malignant tissue during surgery in patients with glioma (suspected WHO grades III or IV on preoperative imaging)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50352156\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Aminolevulinic acid (systemic) may be confused with aminolevulinic acid (topical), methyl aminolevulinate.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50274780\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Aphasia (8%), hemiparesis (8%), headache (3%), hemiplegia (2%), seizure (2%), hypoesthesia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased gamma-glutamyl transferase (grade &ge;2: 8% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&gt;1%), vomiting (&gt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (grade &ge;2: 3% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Monoplegia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Hemianopia (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&gt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Ataxia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal hepatic function tests, anaphylactic shock, angioedema, cerebral edema, chills, diarrhea, erythema, fixed drug eruption, metabolic acidosis, skin photosensitivity, solar dermatitis, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193061\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to aminolevulinic acid or any component of the formulation; hypersensitivity to porphyrins; acute or chronic types of porphyria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50352161\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions (including serious hypersensitivity) have occurred; these reactions include anaphylactic shock, swelling, and urticaria. Cardiopulmonary resuscitation personnel and equipment should be readily available. Monitor all patients for hypersensitivity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitivity: Reduce exposure to sunlight or room lights for 24 hours postoperatively. Due to the risk of phototoxic reactions, do not administer other phototoxic medications for 24 hours before and after systemic aminolevulinic acid administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Should only be used by neurosurgeons who have completed a training program on use of fluorescence in surgery. Aminolevulinic acid must be used with a standard surgical operating microscope adapted with a blue light emitting light source (power density 40 to 80 mW/cm<sup>2</sup>) and ancillary excitation and emission filters to visualize fluorescence excitation in the wavelength of 375 to 440 nm and for observation from 620 to 710 nm (filters transmit porphyrin fluorescence as red-violet, as well as a fraction of backscattered blue excitation light necessary for distinguishing nonfluorescing tissue).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Misinterpretation: Errors may occur with the use of systemic aminolevulinic acid for intraoperative visualization of malignant glioma (including false negatives and false positives)<i>. </i>Non-fluorescing tissue in the surgical field does not rule out the presence of tumor in patients with glioma. Fluorescence may be observed in areas of inflammation or metastases due to other tumor types.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50305332\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50305329\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=113611&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Photosensitizing Agents: May enhance the photosensitizing effect of Aminolevulinic Acid (Systemic).<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50352158\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50352159\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if aminolevulinic acid (systemic) is present in breast milk. The manufacturer recommends breastfeeding women pump and discard breast milk for 24 hours (5 to 6 half-lives) after aminolevulinic acid (systemic) administration to decrease exposure to the breastfed infant.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50352179\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for signs/symptoms of hypersensitivity reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50352165\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;\">Aminolevulinic acid (ALA) occurs endogenously as a metabolite formed in the mitochondria from succinyl-CoA and glycine. Exogenous administration of systemic ALA leads to accumulation of the ALA metabolite, PpIX in tumor cells. During glioma surgery, systemic ALA is used in conjunction with an operating microscope adapted with a blue emitting light source (power density 40 to 80 mW/cm<sup>2</sup>) and filters for excitation light of wavelength 375 to 440 nm, and observation at wavelengths of 620 to 710 nm, allowing tumor tissue to be visualized as red fluorescence (tissue lacking sufficient PpIX concentrations appear blue).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50352166\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Metabolized to PpIX (actual fraction of administered aminolevulinic acid [ALA] that is metabolized to PpIX is unknown).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: 100% (range: 78.5% to 131.2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Oral: ALA: 0.9 &plusmn; 1.2 hours (range: 0.8 to 1.3 hours); PpIX: 3.6 &plusmn; 1.8 hours (range: 1.2 to 7.8 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Oral: 0.8 hours (range: 0.5 to 1 hour); PpIX: 4 hours (range: 1.2 to 7.8 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (27% to 57%; as parent drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50351990\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alaglio (JP);</li>\n      <li>Alasense (RU);</li>\n      <li>Gliolan (AT, AU, BE, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IL, KR, LT, LV, MT, NL, NO, NZ, PL, PT, RO, SE, SI, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Gleolan (aminolevulinic acid hydrochloride) [prescribing information]. Louisville, KY: NX Development Corp; June 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 113611 Version 8.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F50213753\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F50352172\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F50352173\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F50352174\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F50352175\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50193062\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F50352177\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F50193060\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F50352156\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F50274780\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F50193061\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F50352161\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F50305332\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F50305329\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F50352158\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F50352159\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F50352179\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F50352165\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F50352166\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F50351990\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/113611|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=aminolevulinic-acid-systemic-patient-drug-information\" class=\"drug drug_patient\">Aminolevulinic acid (systemic): Patient drug information</a></li></ul></div></div>","javascript":null}